s

What is an Anti-idiotypic Antibody?

s

Technical articles featuring applications of anti-idiotypic antibodies.

s

Request Bulk Quote
Follow us on:

Facebook Linkedin YouTube WeChat

Antibodies for bioanalysis and drug monitoring of risankizumab

Develop highly selective and sensitive PK and ADA assays for the humanized antibody drug risankizumab (Skyrizi) using our range of ready-made anti-idiotypic antibodies.

  • Inhibitory antibodies specific to risankizumab
  • Fully human surrogate positive control or calibrator
  • Sequence defined, well characterized reagents with secure supply
  • Recombinant production, stringent quality control for batch to batch consistency
  • Non-animal-derived antibodies, reducing the use of animals in science

Table 1. Antibodies Specific to Risankizumab

Specificity
Binding Type

Catalog Number

Clone

Format

Affinity* KD, nM

Assay Recommendation

Product Details

Risankizumab Inhibitory

Type 1

HCA414

AbD59012ia

hIgG1

0.1

ADA assay

Order HCA414

HCA415

AbD59005ia

hIgG1

5

ADA assay

Order HCA415

HCA416

AbD59011ia

hIgG1

8

ADA assay

Order HCA416

TZA058

AbD59012ad

Fab-F-Spy2-H1

0.1

PK bridging ELISA (capture)

Order TZA058

TZA059

AbD58231ad

Fab-F-Spy2-H1

0.2

PK bridging ELISA (detection)

Order TZA059

TZA059P

AbD58231pap

Fab2-FH-X22-HRP2

0.2

PK bridging ELISA (detection)

Order TZA059P

* Affinity measured in the monovalent Fab format
1 Fab-F-Spy2-H = Monovalent Fab antibody with (F) DYKDDDDK, (Spy2) SpyTag version 2, and (H) His-6-tags.
2 Fab2-FH-X22-HRP= Bivalent Fab antibody with (F) DYKDDDDK, (H) His-6-tags and Fab-SpyTag coupled to HRP conjugated BiCatcher

Anti-Risankizumab Inhibitory Antibodies (Type 1)

Type 1 anti-risankizumab antibodies inhibit the binding of the drug risankizumab to its target, human interleukin-23 (IL-23). They are ideal for the development of a pharmacokinetic (PK) bridging ELISA to measure free drug. The antibodies, in fully human IgG1 format are suitable as surrogate positive controls or calibrators for an anti-drug antibody (ADA) assay.

ELISA Protocols to Get You Started

PK Bridging ELISA

PK Bridging ELISA: TZA058 (capture) and TZA059P (detection)

Fig. 1. Avelumab PK bridging ELISA using antibodies TZA041 and TZA040P.

Fig. 1. Risankizumab PK bridging ELISA using antibodies TZA058 and TZA059P.

Schematic image of PK bridging ELISA measuring free drug. Anti-idiotypic capture antibody, Fab format (purple), monoclonal antibody drug (gold), anti-idiotypic detection antibody, Fab format (purple) labeled with HRP.

Schematic image of PK bridging ELISA measuring free drug. Anti-idiotypic capture antibody, Fab format (purple), monoclonal antibody drug (gold), anti-idiotypic detection antibody, Fab format (purple) labeled with HRP.

ADA Bridging ELISA

ADA Bridging ELISA: HCA414, HCA415, HCA416

Fig. 2. Risankizumab ADA bridging ELISA using antibodies HCA414, HCA415 and HCA416

Fig. 2. Risankizumab ADA bridging ELISA using antibodies HCA414, HCA415, and HCA416.

Schematic image of ADA bridging assay. Monoclonal antibody drug as capture antibody and detection antibody labeled with HRP (gold), fully human anti-idiotypic antibody, Ig format (blue).

Schematic image of ADA bridging assay. Monoclonal antibody drug as capture antibody and detection antibody labeled with HRP (gold), fully human anti-idiotypic antibody, Ig format (blue).

Resources

Anti-idiotypic antibodies, their binding types and properties

Anti-biotherapeutic antibody quality control and characterization

Custom anti-idiotypic antibody generation service

Licensed Use: For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.